Critical Review: Q32 Bio (QTTB) and Its Competitors

Q32 Bio (NASDAQ:QTTB) is one of 1,000 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Q32 Bio to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.

Valuation and Earnings

This table compares Q32 Bio and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Q32 Bio	$1.16 million	-$112.96 million	-0.75
Q32 Bio Competitors	$1.68 billion	$146.16 million	-1.64

Q32 Bio’s rivals have higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and price targets for Q32 Bio and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0	0	2	0	3.00
Q32 Bio Competitors	6394	18743	44698	918	2.57

Q32 Bio presently has a consensus price target of $47.50, indicating a potential upside of 80.75%. As a group, “Pharmaceutical preparations” companies have a potential upside of 78.62%. Given Q32 Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than its rivals.

Institutional & Insider Ownership

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Q32 Bio has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Q32 Bio’s rivals have a beta of 1.09, indicating that their average stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Q32 Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	-102.52%	-74.91%
Q32 Bio Competitors	-2,459.06%	-249.83%	-30.60%

Summary

Q32 Bio beats its rivals on 7 of the 13 factors compared.

Q32 Bio Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.